European Medicines Agency reviewing reports of kidney injury in patients taking Gilead's remdesivir

The European Medicines Agency is starting a review of Gilead's remdesivir after reports that some patients taking the drug developed acute kidney injury.

The agency said a safety committee will determine if there's a causal relationship between remdesivir and acute kidney injury and will update the drug's guidance for usage accordingly.